Support Care Cancer:透明质酸可有效缓解放疗引起的皮肤粘膜副作用

2022-05-30 MedSci原创 MedSci原创

放疗(RT)癌症患者常用的辅助治疗方法,但是RT引起的皮肤粘膜副作用仍然是困扰癌症患者治疗的一大挑战。透明质酸(HA)皮肤细胞外基质的主要成分,也是组织再生的一个关键分子,可以缓解这些副作用。

放疗(RT)癌症患者常用的辅助治疗方法,但是RT引起的皮肤粘膜副作用仍然是困扰癌症患者治疗的一大挑战。透明质酸(HA)皮肤细胞外基质的主要成分,也是组织再生的一个关键分子,可以缓解这些副作用。近日,发表于Support Care Cancer的一项系统回顾和荟萃分析评估了HA对癌症患者的RT诱发的副作用的影响。

研究人员检索了PubMed、Embase和Cochrane图书馆收录的已发表的比较了HA应用于准备接受或已经接受RT治疗的癌症患者的结果的随机对照试验(RCTs),进行了系统回顾和荟萃分析,使用随机效应模型计算集合效应大小。

 

结果,研究共纳入了15项试验,包括1131名患者。分析结果显示,与对照组相比,HA组在第4周时皮肤疼痛评分有明显改善(平均差异[MD]:-1.14,95%置信区间[CI]:-2.21至-0.08),在5-8周时疼痛频率明显降低(风险比[RR]:0.47,95%CI:0.24至0.93)。与对照组相比,HA组在4-5周时脱屑发生率(RR:0.27,95%CI:0.15至0.5)和严重粘膜问题的发生率(RR:0.14,95%CI:0.04至0.45)也明显降低。此外,在4个月和18个月时,HA组的出血发生率明显低于对照组(RR:0.18,95%CI:0.05至0.65)。

综上所述,该研究结果表明,HA治疗可减少RT引起的粘膜问题和疼痛。此外,HA治疗没有严重不良事件的报道。因此,对于癌症患者的RT诱发的粘膜副作用,HA是一种安全和可行的治疗方法。但是,仍需要大型试验纳入更多的患者以验证该研究发现。

 

原始出处:

 

Ruo-Zhu Tai, et al.,  Effect of hyaluronic acid on radiotherapy-induced mucocutaneous side effects: a meta-analysis of randomized controlled trials. Support Care Cancer. 2022 Jun;30(6):4845-4855. doi: 10.1007/s00520-022-06902-0.  

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1824388, encodeId=6d0918243882c, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Wed Jan 11 11:53:45 CST 2023, time=2023-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795212, encodeId=98a91e9521230, content=<a href='/topic/show?id=5cd1169138f' target=_blank style='color:#2F92EE;'>#support#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16913, encryptionId=5cd1169138f, topicName=support)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Tue Nov 01 17:53:45 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691107, encodeId=a8ba169110e9b, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Tue Feb 14 07:53:45 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276761, encodeId=240112e676128, content=<a href='/topic/show?id=ec9e9482383' target=_blank style='color:#2F92EE;'>#透明质酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94823, encryptionId=ec9e9482383, topicName=透明质酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Thu May 19 04:53:45 CST 2022, time=2022-05-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1824388, encodeId=6d0918243882c, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Wed Jan 11 11:53:45 CST 2023, time=2023-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795212, encodeId=98a91e9521230, content=<a href='/topic/show?id=5cd1169138f' target=_blank style='color:#2F92EE;'>#support#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16913, encryptionId=5cd1169138f, topicName=support)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Tue Nov 01 17:53:45 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691107, encodeId=a8ba169110e9b, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Tue Feb 14 07:53:45 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276761, encodeId=240112e676128, content=<a href='/topic/show?id=ec9e9482383' target=_blank style='color:#2F92EE;'>#透明质酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94823, encryptionId=ec9e9482383, topicName=透明质酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Thu May 19 04:53:45 CST 2022, time=2022-05-19, status=1, ipAttribution=)]
    2022-11-01 wetgdt
  3. [GetPortalCommentsPageByObjectIdResponse(id=1824388, encodeId=6d0918243882c, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Wed Jan 11 11:53:45 CST 2023, time=2023-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795212, encodeId=98a91e9521230, content=<a href='/topic/show?id=5cd1169138f' target=_blank style='color:#2F92EE;'>#support#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16913, encryptionId=5cd1169138f, topicName=support)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Tue Nov 01 17:53:45 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691107, encodeId=a8ba169110e9b, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Tue Feb 14 07:53:45 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276761, encodeId=240112e676128, content=<a href='/topic/show?id=ec9e9482383' target=_blank style='color:#2F92EE;'>#透明质酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94823, encryptionId=ec9e9482383, topicName=透明质酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Thu May 19 04:53:45 CST 2022, time=2022-05-19, status=1, ipAttribution=)]
    2023-02-14 guoyibin
  4. [GetPortalCommentsPageByObjectIdResponse(id=1824388, encodeId=6d0918243882c, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Wed Jan 11 11:53:45 CST 2023, time=2023-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795212, encodeId=98a91e9521230, content=<a href='/topic/show?id=5cd1169138f' target=_blank style='color:#2F92EE;'>#support#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16913, encryptionId=5cd1169138f, topicName=support)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Tue Nov 01 17:53:45 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691107, encodeId=a8ba169110e9b, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Tue Feb 14 07:53:45 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276761, encodeId=240112e676128, content=<a href='/topic/show?id=ec9e9482383' target=_blank style='color:#2F92EE;'>#透明质酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94823, encryptionId=ec9e9482383, topicName=透明质酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Thu May 19 04:53:45 CST 2022, time=2022-05-19, status=1, ipAttribution=)]

相关资讯

放疗常见的5大副作用,该如何应对?

当射线穿透人体组织达到肿瘤时,不可避免会对正常组织造成损伤。

伤心总是难免的?乳腺癌放疗显著加速冠脉钙化进展!

Radiat Oncol:乳腺癌患者放疗后冠状动脉钙化负荷的加速:与年龄和种族匹配的健康女性的比较

放疗常见副作用及处理方法,看这一篇就够了

一文理清放疗副作用及应对策略!

Br J Cancer:5-氨基酮戊酸增加线粒体活性氧的产生降低前列腺癌的放疗抗性

5-ALA联合放射性疗法的治疗策略能够提高放疗对前列腺癌的治疗效果

Eur Urol Oncol:局部消融放疗在寡转移PCa患者中的疗效如何?

调查了aRT对使用镓-68前列腺特异性膜抗原靶向正电子发射断层扫描(PSMA-PET)分期的寡转移性PCa患者,是否是安全和有效的。

J Urol:在高危和极高危前列腺癌患者中,根治性前列腺切除术与放射治疗哪个生存率更高?

在美国国家综合癌症网络(NCCN)高危(HR)患者以及约翰霍普金斯大学(JH)高危(HR)和极高危(VHR)亚组中,比较了前列腺根治术(RP)与体外放疗(EBRT)的癌症特异性死亡率(CSM)情况。